Guardant Health Wins 2026 Prix Galien USA Award for Shield Blood Test, Recognized for Advancing Colorectal Cancer Screening
Recognition for Innovation in Medical Technology
Guardant Health, a precision oncology company focused on improving cancer detection and treatment, has announced that its Shield™ blood test has received the 2026 Prix Galien USA Award for Best Medical Technology. The award recognizes Shield for its role in expanding patient choice and encouraging greater participation in colorectal cancer (CRC) screening. The recognition highlights the company’s efforts to make cancer screening more accessible through blood-based testing.
Shield is designed to detect colorectal cancer through a blood test and is the first blood-based test to receive approval from the U.S. Food and Drug Administration (FDA) for primary colorectal cancer screening. The technology offers an additional screening option for eligible individuals, particularly those who may be less likely to complete traditional screening methods. Guardant Health said the award reflects the test’s contribution to improving access to screening and addressing gaps in CRC screening participation.
The Prix Galien USA Awards recognize scientific and technological developments that contribute to improving human health. Established in 2007, the awards have become an important recognition program within the life sciences sector, highlighting innovations across multiple areas of healthcare. The 2026 awards recognized achievements across eight key categories, with Shield receiving the distinction in the medical technology category.
The selection process involved a committee comprising prominent scientific leaders, Nobel laureates and industry executives. These experts evaluated innovations for their contributions to healthcare and their potential to improve patient outcomes. Shield’s selection reflects the growing role of blood-based diagnostic technologies in cancer screening and the wider healthcare industry’s interest in developing more accessible approaches to early detection.
Shield Aims to Expand Colorectal Cancer Screening Access
Colorectal cancer screening plays an important role in identifying cancer at an earlier stage and supporting timely medical evaluation. However, screening participation remains a challenge, as some individuals do not complete recommended screening procedures. Factors such as concerns about preparation, inconvenience, access to healthcare services and reluctance to undergo certain procedures can influence whether people participate in screening programs.
Guardant Health developed Shield to provide an alternative screening option through a blood-based approach. By using a blood sample, the test offers a different experience from established screening methods that may involve stool sample collection or more extensive preparation. The availability of another screening option can help healthcare providers discuss screening preferences with patients and encourage more people to take part in recommended screening.
The company believes that expanding patient choice is an important part of improving population-level screening rates. When individuals have access to screening options that better match their preferences, they may be more willing to complete the process. Shield is intended to contribute to this approach by providing a blood-based option within the broader colorectal cancer screening landscape.
The Prix Galien recognition also draws attention to the importance of developing diagnostic technologies that address practical barriers to healthcare participation. While scientific performance remains essential, the ability of a screening test to reach people and encourage them to complete recommended procedures is another important consideration for public health.
More Than a Decade of Blood-Based Testing Innovation
According to Guardant Health, Shield is built on more than a decade of research and proprietary innovation in blood-based testing. The company’s work in precision oncology has focused on using blood samples to identify information relevant to cancer detection and treatment. This approach is part of a broader movement toward less invasive diagnostic technologies that can support clinical decision-making.
Blood-based testing has attracted increasing attention because it can provide healthcare professionals with information through a relatively straightforward sample collection process. In cancer screening, such technologies may offer an additional pathway for individuals who are reluctant to use other established methods. Guardant Health has positioned Shield within this developing field, with the goal of making colorectal cancer screening more convenient for patients.
AmirAli Talasaz, co-CEO of Guardant Health, said the recognition affirms the purpose behind the development of Shield: improving population health by making colorectal cancer screening more accessible. He highlighted the company’s investment in blood-based testing innovation and the test’s reported ability to increase screening adherence in real-world settings.
Talasaz also emphasized that improving screening participation is central to the company’s mission to help close the colorectal cancer screening gap in the United States. The award, therefore, represents recognition not only of the technology itself but also of its intended role in encouraging more individuals to complete screening.
Inclusion in Major Clinical Guidelines
Shield is included in guidelines from the American Cancer Society and the National Comprehensive Cancer Network (NCCN), according to Guardant Health. These organizations publish recommendations and guidance that help inform cancer screening and clinical care. Inclusion in their guidelines provides healthcare professionals with additional information when considering screening approaches for appropriate patients.
The American Cancer Society develops recommendations intended to support cancer prevention, early detection and improved outcomes. The NCCN brings together experts from leading cancer centers to develop clinical practice guidelines covering cancer screening, diagnosis and treatment. Their guidance is widely used by healthcare professionals when making decisions about patient care.
Guardant Health describes Shield as the most clinically validated blood test on the market. The company’s statement reflects its assessment of the available clinical evidence supporting the technology. The inclusion of Shield in major guidelines also places the test within the broader framework of established screening recommendations.
For patients and healthcare providers, the availability of different screening methods can support more individualized discussions. Screening decisions may depend on a person’s medical history, risk factors, preferences and the recommendations of their healthcare professional. Blood-based testing adds another option to these conversations, while follow-up care remains an important part of the screening process.
Real-World Use Demonstrates Screening Participation
Guardant Health reported that more than 200,000 Shield tests have been performed in real-world settings. The company said the test has demonstrated an ability to significantly increase overall colorectal cancer screening completion among patients, with screening adherence exceeding 90%.
These figures highlight the company’s focus on measuring the practical impact of the technology beyond its development and clinical evaluation. Real-world use can provide information about how patients and healthcare providers engage with a screening option after it becomes available in routine healthcare settings. In particular, screening adherence is an important measure because a test can only contribute to early detection when individuals actually complete the screening process and receive appropriate follow-up.
The reported adherence rate is particularly relevant to the challenge of increasing colorectal cancer screening participation. Healthcare organizations continue to look for approaches that can encourage eligible individuals to complete recommended screening. Offering additional choices may help address some of the barriers that prevent people from participating.
However, screening completion is only one part of the overall process. When a screening test indicates a need for further evaluation, timely follow-up is essential. For colorectal cancer screening, colonoscopy can play an important role in investigating abnormal findings and identifying potential disease. Ensuring that patients complete recommended follow-up procedures is therefore a key consideration when evaluating the broader impact of screening programs.
Modeling Study Examines the Role of Follow-Up Colonoscopy
Guardant Health also highlighted a recent modeling study that examined the potential long-term impact of blood-based colorectal cancer screening. The study evaluated outcomes over an individual’s lifetime and considered how different screening approaches could influence follow-up colonoscopy adherence. It compared Shield with fecal immunochemical testing (FIT) and multitarget stool DNA (mt-sDNA) testing.
According to the company, the modeling results demonstrated that Shield led to increased colonoscopy completion compared with the two stool-based testing approaches. The study also indicated that the use of Shield was associated with more colorectal cancer deaths averted over a lifetime in the modeled population. These findings highlight the potential importance of considering not only the initial screening test but also whether individuals proceed with recommended follow-up procedures.
FIT and mt-sDNA tests are established stool-based approaches used in colorectal cancer screening. They provide alternatives to other screening methods and are included in screening strategies recommended for appropriate populations. However, the effectiveness of any screening pathway depends on patient participation and completion of subsequent diagnostic procedures when needed.
The modeling study suggests that blood-based screening may influence the overall screening pathway by encouraging more individuals to complete both the initial test and follow-up colonoscopy. This is an important consideration because the benefits of screening depend on the full sequence of care, from initial testing through diagnostic evaluation and, when necessary, treatment.
It is important to distinguish modeled outcomes from results observed in a completed clinical trial or population-wide screening program. Modeling studies use assumptions and available data to estimate potential outcomes over time. Their findings can help researchers and healthcare organizations understand possible benefits, but real-world results may vary depending on patient characteristics, clinical practices and follow-up rates.
Addressing the Colorectal Cancer Screening Gap
Increasing participation in colorectal cancer screening remains an important public health objective. Screening can help identify potential signs of cancer before symptoms develop, allowing healthcare professionals to investigate findings and determine whether additional care is necessary. Yet the availability of screening recommendations does not automatically ensure that people complete the process.
Some individuals may delay screening because they are uncomfortable with particular testing methods. Others may face practical challenges involving scheduling, access to healthcare facilities or the time required to complete certain procedures. These barriers can contribute to gaps in screening participation, making it important to develop approaches that accommodate different patient needs.
Shield is intended to help address these challenges by offering a blood-based screening option. Its availability may allow healthcare professionals to discuss another method with patients who are hesitant to complete other forms of screening. By providing additional choice, the test may help bring more individuals into screening programs.
Guardant Health’s emphasis on screening adherence reflects the importance of making diagnostic technologies practical for routine healthcare use. A screening test’s potential public health contribution depends not only on its technical capabilities but also on whether patients are willing and able to use it. The company’s reported real-world experience and modeling findings are being presented as evidence of Shield’s potential role in this area.
Prix Galien Award Highlights the Growing Role of Diagnostic Technology
The 2026 Prix Galien USA Award adds to the recognition of blood-based testing as an emerging area of medical technology. Advances in molecular diagnostics and precision oncology are creating new opportunities to use blood samples in cancer-related healthcare. These developments are influencing how companies approach cancer detection, patient monitoring and clinical decision-making.
The Prix Galien program recognizes innovations that demonstrate contributions to the life sciences and human health. Its medical technology category highlights developments that introduce new capabilities or improve existing approaches to healthcare. Shield’s selection places the test among the technologies recognized by the 2026 committee for their contribution to the medical technology field.
For Guardant Health, the award provides recognition of its work in developing blood-based colorectal cancer screening. It also reinforces the company’s broader objective of applying precision oncology technologies to improve cancer detection and care. The recognition comes as healthcare providers continue to evaluate how emerging diagnostic options can complement established screening methods.
The award does not replace the need for continued clinical evaluation, guideline-based screening decisions or appropriate follow-up care. Instead, it highlights the potential value of technologies that aim to improve access and encourage participation in preventive healthcare.
Guardant Health Continues Its Focus on Improving Cancer Detection
Guardant Health’s recognition at the 2026 Prix Galien USA Awards highlights the company’s efforts to expand the use of blood-based testing in cancer screening. Through Shield, the company is seeking to provide an additional option for colorectal cancer screening while addressing barriers that can prevent individuals from completing recommended tests.
The reported experience of more than 200,000 tests performed in real-world settings, along with screening adherence exceeding 90%, forms a central part of the company’s case for the technology. The modeling study comparing Shield with FIT and mt-sDNA testing further highlights the potential importance of follow-up colonoscopy completion in achieving long-term screening benefits.
As blood-based diagnostic technologies continue to develop, their role in healthcare will depend on clinical evidence, patient participation, guideline recommendations and the ability to connect screening results with appropriate medical care. Shield’s inclusion in American Cancer Society and NCCN guidelines, as reported by Guardant Health, represents an important part of its position in the current screening landscape.
The 2026 Prix Galien USA Award recognizes Shield’s contribution to medical technology and its goal of making colorectal cancer screening more accessible. For Guardant Health, the recognition supports its ongoing mission to help close screening gaps and expand patient choice through precision oncology innovation.
Source link: https://investors.guardanthealth.com/
